Article

Clinical focus for incontinentia pigmenti requires redirection

Coronado Island, CA-The focus of attention in caring for babies with incontinentia pigmenti (IP) should be on the potential for rapid development of irreversible blindness rather than on the clinically obvious skin manifestations, said Morton F. Goldberg, MD, in the Gertrude D. Pyron Award Lecture at the annual meeting of the American Society of Retina Specialists.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Related Content
(Image credit: AdobeStock/Vitalii Vodolazskyi) Yale researchers identify corneal ulcer pathogens by testing tears
July 1st 2025

Yale researchers identify corneal ulcer pathogens by testing tears

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/WS Studio 1985)
June 25th 2025

Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Expanding access, enhancing research: The evolving landscape of ophthalmic clinical trials
June 23rd 2025

Expanding access, enhancing research: The evolving landscape of ophthalmic clinical trials

(Image credit: AdobeStock/Justlight)
June 18th 2025

Ruth Hogg, PhD, on what retinal imaging can tell clinicians about the brain and body

© 2025 MJH Life Sciences

All rights reserved.